CYP3A is an enzyme subfamily in the cytochrome P450 (CYP) superfamily and includes
isoforms CYP3A4, CYP3A5, CYP3A7, and CYP3A43. CYP3A enzymes are indiscriminate …

Cytochrome P450 3A4 (CYP3A4), one of the most important members of the cytochrome
P450 subfamily, is a crucial catalyst in the metabolism of numerous drugs. As it catalyzes …

Background Oral targeted therapies show a high pharmacokinetic (PK) interpatient
variability. Even though exposure has been positively correlated with efficacy for many of …

Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes
that are involved in multiple cellular processes. Currently, multiple oral TKIs have been …

Anti-angiogenic treatment is an important option that has changed the therapeutic
landscape in various tumors, particularly in patients affected by renal cell carcinoma (RCC) …

Cannabis and related compounds have created significant research interest as a promising
therapy in many disorders. However, the individual therapeutic effects of cannabinoids and …

The CYP3A subfamily, which includes isoforms CYP3A4, CYP3A5, and CYP3A7 in humans,
plays important roles in the metabolism of various endogenous and exogenous substances …

Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the
liver, responsible for the oxidative metabolism of∼ 50% of clinically prescribed drugs …

Lapatinib is a dual tyrosine kinase inhibitor associated with rare but potentially severe
idiosyncratic hepatotoxicity. We have previously shown that cytochromes P450 CYP3A4 and …

Purpose Pazopanib is approved in advanced renal cell carcinoma (RCC) and soft-tissue
sarcoma at a flat-fixed dose despite a large pharmacokinetics interindividual variability and …